#6/A 3/10/01

MAR 0 6 2002 ECH CENTER 1600/2900

2

FEB 2 2 2002 115

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Dominguez et al.

Serial No.:

09/732,546

Group Art Unit No.: 1624

Filed:

December 8, 2000

Examiner: Rao, Deepak R

For:

Integrin Inhibitors and Their Methods of Use

Docket No.:

A-648

ELECTION AND AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is a response to the Office Action mailed 28 January 2002.

AMENDMENT

In the Specification:

Please replace the first full paragraph of page 3 with the following:

a'

Integrin $\alpha_v \beta_6$ is an RGD, tenascin and fibronectin binding protein (J. Biol. Chem. 267:5790-6, 1992) which is expressed by a number of cells, such as carcinoma and epithelial cells, and is thought to be involved in carcinoma cell proliferation (J. Cell Biol. 127:547-56, 1994), in wound healing and cell attachment (J. Invest. Dermatol. 106:42-8, 1996), in epithelial inflammation, such as asthma (J. Cell Biol. 133:921-928, 1996), in inducing gelatinase B secretion, activation of the protein kinase-C pathway, tumor cell spreading and proliferation in colon cancer cells (Biochem. Biophys. Res. Commun. 249:287-291, 1998; Int. J. Cancer 81:90-97, 1999), in regulation of pulmonary inflammation and fibrosis and binding and activating

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number: EL198797788US

Date of Deposit February 22, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, U.S. Patent and Trademack Office, 2900 Crystal Driver Arlington, VA 22202.

Lynne Buchsbaum

Trademark Office, 2900 Cr

Signature Signature